Amphastar Pharmaceuticals, Inc.
AMPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,239 | $1,078 | $1,381 | $1,798 |
| - Cash | $217 | $188 | $183 | $152 |
| + Debt | $657 | $655 | $653 | $651 |
| Enterprise Value | $1,679 | $1,546 | $1,851 | $2,297 |
| Revenue | $192 | $174 | $171 | $187 |
| % Growth | 10% | 2.3% | -8.6% | – |
| Gross Profit | $99 | $86 | $85 | $87 |
| % Margin | 51.4% | 49.6% | 50% | 46.5% |
| EBITDA | $42 | $62 | $52 | $65 |
| % Margin | 21.9% | 35.5% | 30.7% | 34.9% |
| Net Income | $17 | $31 | $25 | $38 |
| % Margin | 9% | 17.8% | 14.8% | 20.4% |
| EPS Diluted | 0.37 | 0.64 | 0.51 | 0.74 |
| % Growth | -42.2% | 25.5% | -31.1% | – |
| Operating Cash Flow | $53 | $36 | $35 | $29 |
| Capital Expenditures | -$5 | -$11 | -$11 | -$12 |
| Free Cash Flow | $47 | $25 | $24 | $17 |